LTS is a pharmaceutical technology company that develops and manufactures drug delivery systems for pharma partners, with a focus on transdermal therapeutic systems (TTS), oral thin films (OTFs) and micro-array patches (MAPs). Its systems are applied in more than 20 marketed products.
LTS Lohmann Therapie-Systeme AG
Phone / ContactT: +49 2632 99 0
F: +49 2632 99 2200
E: [email protected]
LTS is a pharmaceutical technology company that develops and manufactures drug delivery systems for the pharmaceutical industry, with a focus on transdermal therapeutic systems (TTS), oral thin films (OTFs) and, more recently, micro-array patches (MAPs).
LTS does not sell its own pharmaceutical products but partners with pharma companies, to which it offers solutions at all stages of drug development from feasibility assessments, new formulation R&D, clinical trials (up to phase II), production and packaging.
The company was founded as LTS Lohman Therapie-System in 1984 to develop transdermal therapeutic systems, as a subsidiary of the Lohmann Group, an adhesive tapes specialist. Since then it has been a pioneer in transdermal drug delivery, being involved in – for example – the development of the first ever nicotine patch to reach the market, the first transdermal hormone product (an estradiol patch), the first contraceptive patch (J&J’s Evra), and the first pain relief patch (buprenorphine). Likewise, in OTF delivery the company is a pioneer, for example, being the manufacturer of the first OTF for breakthrough cancer pain.
LTS Lohman Therapie-System AG is a non-listed public limited company, with locations in the West Caldwell, NJ, US and Shanghai, China, in addition to its German headquarters. It employs more than >1,100 people and has a turnover of >€300 million.